ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
Read More